Cullinan Therapeutics (CGEM) Short Interest Ratio & Short Volume $7.64 +0.37 (+5.09%) Closing price 04:00 PM EasternExtended Trading$7.64 0.00 (0.00%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cullinan Therapeutics Short Interest DataCullinan Therapeutics (CGEM) has a short interest of 5.88 million shares, representing 16.37% of the float (the number of shares available for trading by the public). This marks a -1.84% decrease in short interest from the previous month. The short interest ratio (days to cover) is 15.6, indicating that it would take 15.6 days of the average trading volume of 333,197 shares to cover all short positions.Current Short Interest5,880,000 sharesPrevious Short Interest5,990,000 sharesChange Vs. Previous Month-1.84%Dollar Volume Sold Short$43.81 millionShort Interest Ratio15.6 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares59,070,000 sharesFloat Size35,920,000 sharesShort Percent of Float16.37%Today's Trading Volume365,458 sharesAverage Trading Volume333,197 sharesToday's Volume Vs. Average110% Short Selling Cullinan Therapeutics? Sign up to receive the latest short interest report for Cullinan Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCGEM Short Interest Over TimeCGEM Days to Cover Over TimeCGEM Percentage of Float Shorted Over Time Cullinan Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/20255,880,000 shares $43.81 million -1.8%16.4%15.6 $7.45 6/30/20255,990,000 shares $45.10 million +0.5%16.7%14.1 $7.53 6/15/20255,960,000 shares $51.32 million -3.6%16.6%13.9 $8.61 5/31/20256,180,000 shares $53.52 million +3.2%17.2%13.7 $8.66 5/15/20255,990,000 shares $43.37 million -19.9%16.7%13 $7.24 4/30/20257,480,000 shares $61.93 million -6.4%20.9%16.2 $8.28 4/15/20257,990,000 shares $62.32 million -6.3%22.5%17.3 $7.80 3/31/20258,530,000 shares $64.57 million -1.6%24.1%18.1 $7.57 3/15/20258,670,000 shares $76.21 million +0.1%24.4%17.7 $8.79 2/28/20258,660,000 shares $73.52 million -1.3%24.4%17.4 $8.49 Get the Latest News and Ratings for CGEM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/20258,770,000 shares $83.58 million +0.5%24.6%17.2 $9.53 1/31/20258,730,000 shares $92.19 million -10.7%23.7%15.7 $10.56 1/15/20259,780,000 shares $99.56 million -0.4%26.6%18.4 $10.18 12/31/20249,820,000 shares $119.61 million +1.8%26.7%19 $12.18 12/15/20249,650,000 shares $113.39 million +5.4%26.0%19.5 $11.75 11/30/20249,160,000 shares $123.20 million +5.2%24.7%16.8 $13.45 11/15/20248,710,000 shares $120.72 million -3.4%23.5%16.2 $13.86 10/31/20249,020,000 shares $140.26 million -0.4%23.0%17.1 $15.55 10/15/20249,060,000 shares $147.13 million -1.6%23.2%15.7 $16.24 9/30/20249,210,000 shares $154.18 million +9.4%23.6%14.2 $16.74 9/15/20248,420,000 shares $151.14 million +4.6%21.6%11.7 $17.95 8/31/20248,050,000 shares $157.78 million -1.4%20.9%10.2 $19.60 8/15/20248,160,000 shares $137.99 million -2.4%21.2%10.3 $16.91 7/31/20248,360,000 shares $161.77 million +6.0%20.6%10 $19.35 7/15/20247,890,000 shares $130.90 million +0.6%19.4%8 $16.59 6/30/20247,840,000 shares $136.73 million +73.5%19.3%8 $17.44 6/15/20244,520,000 shares $85.34 million +4.2%10.3%5.1 $18.88 5/31/20244,340,000 shares $101.99 million +16.0%11.0%5.5 $23.50 5/15/20243,740,000 shares $99.93 million +58.5%11.9%5 $26.72 4/30/20242,360,000 shares $63.74 million +40.5%10.2%3.3 $27.01 4/15/20241,680,000 shares $27.80 million +16.7%6.4%3.1 $16.55 3/31/20241,440,000 shares $24.54 million +53.9%5.5%3.4 $17.04 3/15/2024935,400 shares $14.90 million +34.8%3.6%2.3 $15.93 2/29/2024694,100 shares $12.82 million -11.5%2.6%1.8 $18.47 2/15/2024783,900 shares $14.45 million -46.7%2.9%2.3 $18.43 1/31/20241,470,000 shares $22.26 million +34.9%5.4%5.1 $15.14 1/15/20241,090,000 shares $11.54 million +3.8%4.0%5.2 $10.59 12/31/20231,050,000 shares $10.70 million -48.5%3.9%5.4 $10.19 12/15/20232,040,000 shares $16.81 million -3.3%7.5%11.1 $8.24 11/30/20232,110,000 shares $17.28 million -2.3%7.8%12.5 $8.19INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off (Ad)Right now, we’re witnessing a monumental shift in the world.Our No. 1 AI Pick is currently trading for pennies on the dollar compared to Nividia. 11/15/20232,160,000 shares $19.16 million +0.5%8.0%13.3 $8.87 10/31/20232,150,000 shares $20.06 million -1.8%7.9%12.9 $9.33 10/15/20232,190,000 shares $19.27 million -0.5%8.1%12.9 $8.80 9/30/20232,200,000 shares $19.91 million +0.9%8.1%12.1 $9.05 9/15/20232,180,000 shares $21.71 million -17.7%8.0%11.5 $9.96 8/31/20232,650,000 shares $27.43 million +33.2%9.8%10.2 $10.35 8/15/20231,990,000 shares $20.32 million +2.6%7.4%6.4 $10.21 7/31/20231,940,000 shares $20.54 million -18.5%8.2%6.1 $10.59 7/15/20232,380,000 shares $27.89 million +15.5%10.1%7.6 $11.72 6/30/20232,060,000 shares $22.17 million -11.6%8.7%6.8 $10.76 6/15/20232,330,000 shares $29.59 million +2.6%9.9%7.6 $12.70 5/31/20232,270,000 shares $23.34 million +0.9%9.6%8.6 $10.28 5/15/20232,250,000 shares $22.37 million +0.5%9.5%10.7 $9.94 4/30/20232,240,000 shares $21.80 million +0.5%9.5%10.7 $9.73 4/15/20232,230,000 shares $22.34 million +0.5%9.5%9.9 $10.02 3/31/20232,220,000 shares $22.71 million +1.8%9.4%10.2 $10.23 3/15/20232,180,000 shares $24.44 million +3.8%7.7%10.5 $11.21 2/28/20232,100,000 shares $23.71 million +1.5%7.0%13.3 $11.29 2/15/20232,070,000 shares $23.91 million +6.7%6.9%13.7 $11.55 1/31/20231,940,000 shares $22.58 million -9.4%6.6%13.7 $11.64 1/15/20232,140,000 shares $23.50 million -1.8%7.2%16.4 $10.98 12/30/20222,180,000 shares $23.00 million No Change7.4%17 $10.55 12/15/20222,180,000 shares $24.96 million No Change7.4%15.9 $11.45 11/30/20222,180,000 shares $27.10 million -5.6%7.4%14.8 $12.43 11/15/20222,310,000 shares $29.48 million -4.9%8.0%14.2 $12.76 10/31/20222,430,000 shares $31.93 million -0.4%8.5%15.4 $13.14 10/15/20222,440,000 shares $30.79 million -1.2%8.5%15.7 $12.62 9/30/20222,470,000 shares $31.67 million +14.4%8.6%14.2 $12.82 9/15/20222,160,000 shares $28.21 million -13.6%7.5%10.9 $13.06 8/31/20222,500,000 shares $33.70 million No Change8.8%10.5 $13.48 8/15/20222,500,000 shares $35.40 million +2.9%8.8%8.5 $14.16 7/31/20222,430,000 shares $32.83 million -17.9%9.9%4.1 $13.51 7/15/20222,960,000 shares $43.57 million -1.7%12.1%4.9 $14.72 6/30/20223,010,000 shares $38.59 million -0.7%12.3%5.2 $12.82 6/15/20223,030,000 shares $36.09 million +6.3%12.4%5.2 $11.91 5/31/20222,850,000 shares $30.47 million +4.0%11.7%5.3 $10.69 5/15/20222,740,000 shares $29.10 million +3.8%11.2%5.7 $10.62 4/30/20222,640,000 shares $25.90 million +7.8%11.2%14.4 $9.81 4/15/20222,450,000 shares $27.44 million -3.5%10.4%13.2 $11.20 3/31/20222,540,000 shares $26.59 million -7.3%11.0%13.3 $10.47 3/15/20222,740,000 shares $34.91 million +1.5%12.1%13.2 $12.74 2/28/20222,700,000 shares $38.72 million +5.9%12.0%10.3 $14.34 2/15/20222,550,000 shares $37.69 million -3.4%11.3%9.6 $14.78 1/31/20222,640,000 shares $35.59 million -13.7%12.1%9.9 $13.48 1/15/20223,060,000 shares $41.89 million -1.0%13.4%11.4 $13.69 12/31/20213,090,000 shares $47.68 million +27.2%14.3%10.7 $15.43 12/15/20212,430,000 shares $38.71 million +3.4%11.2%9.4 $15.93 11/30/20212,350,000 shares $42.30 million -0.8%10.9%9.9 $18.00 11/15/20212,370,000 shares $49.68 million -7.8%8.1%9.3 $20.96 10/29/20212,570,000 shares $57.11 million +0.8%8.9%10.3 $22.22INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off (Ad)Right now, we’re witnessing a monumental shift in the world.Our No. 1 AI Pick is currently trading for pennies on the dollar compared to Nividia. 10/15/20212,550,000 shares $63.75 million -1.9%8.8%10.6 $25.00 9/30/20212,600,000 shares $58.68 million +42.9%9.0%11.7 $22.57 9/15/20211,820,000 shares $52.78 million -24.5%6.3%7.6 $29.00 8/31/20212,410,000 shares $68.01 million -11.1%8.4%11.7 $28.22 8/13/20212,710,000 shares $75.09 million No Change9.5%12.4 $27.71 CGEM Short Interest - Frequently Asked Questions What is Cullinan Therapeutics' current short interest? Short interest is the volume of Cullinan Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 5,880,000 shares of CGEM short. 16.37% of Cullinan Therapeutics' shares are currently sold short. Learn More on Cullinan Therapeutics' current short interest. What is a good short interest ratio for Cullinan Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CGEM shares currently have a short interest ratio of 16.0. Learn More on Cullinan Therapeutics's short interest ratio. What is a good short interest percentage for Cullinan Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 16.37% of Cullinan Therapeutics' floating shares are currently sold short. Is Cullinan Therapeutics' short interest increasing or decreasing? Cullinan Therapeutics saw a decline in short interest during the month of July. As of July 15th, there was short interest totaling 5,880,000 shares, a decline of 1.8% from the previous total of 5,990,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cullinan Therapeutics' float size? Cullinan Therapeutics currently has issued a total of 59,070,000 shares. Some of Cullinan Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cullinan Therapeutics currently has a public float of 35,920,000 shares. How does Cullinan Therapeutics' short interest compare to its competitors? 16.37% of Cullinan Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cullinan Therapeutics: Vericel Corporation (10.60%), Apogee Therapeutics Inc. (24.62%), Tarsus Pharmaceuticals, Inc. (19.45%), Arcutis Biotherapeutics, Inc. (14.40%), ARS Pharmaceuticals, Inc. (26.75%), Immunocore Holdings PLC Sponsored ADR (17.36%), Adaptive Biotechnologies Corporation (6.36%), Sarepta Therapeutics, Inc. (15.21%), Edgewise Therapeutics, Inc. (14.36%), Biohaven Ltd. (13.20%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Cullinan Therapeutics stock? Short selling CGEM is an investing strategy that aims to generate trading profit from Cullinan Therapeutics as its price is falling. CGEM shares are trading up $0.38 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cullinan Therapeutics? A short squeeze for Cullinan Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CGEM, which in turn drives the price of the stock up even further. How often is Cullinan Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CGEM, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies VCEL Short Interest Data APGE Short Interest Data TARS Short Interest Data ARQT Short Interest Data SPRY Short Interest Data IMCR Short Interest Data ADPT Short Interest Data SRPT Short Interest Data EWTX Short Interest Data BHVN Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CGEM) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access